|
1
|
Fearon C, Loftus T, Byrne AL, Heffernan J,
Cooney M, Heeney C, Walsh A, Lorigan J, Beausang A, Cryan J, et al:
Impact of the 2016 world health organization classification of
tumours of the central nervous system: An Irish experience. Ir J
Med Sci. 189:799–803. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegelin MD, Schneider E, Westhoff MA,
Wirtz CR and arpel-Massler G: Current state and future perspective
of drug repurposing in malignant glioma. Semin Cancer Biol. Nov
14–2019.(Epub ahead of print). doi:
10.1016/j.semcancer.2019.10.018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tamura R, Miyoshi H, Yoshida K, Okano H
and Toda M: Recent progress in the research of suicide gene therapy
for malignant glioma. Neurosurg Rev. Nov 28–2019.(Epub ahead of
print). doi: 10.1007/s10143-019-01203-3. View Article : Google Scholar
|
|
4
|
Song T, Zhang X, Wang C, Wu Y, Cai W, Gao
J and Hong B: MiR-138 suppresses expression of hypoxia-inducible
factor 1α (HIF-1α) in clear cell renal cell carcinoma 786-O cells.
Asian Pac J Cancer Prev. 12:1307–1311. 2011.PubMed/NCBI
|
|
5
|
Islam M, Datta J, Lang JC and Teknos TN:
Down regulation of RhoC by microRNA-138 results in de-activation of
FAK, Src and Erk1/2 signaling pathway in head and neck squamous
cell carcinoma. Oral Oncol. 50:448–456. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu Z, Tang J, Wang J, Duan G, Zhou L and
Zhou X: MiR-138 acts as a tumor suppressor by targeting EZH2 and
enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS
One. 11:e01500262016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiao L, Zhou H, Li XP, Chen J, Fang C, Mao
CX, Cui JJ, Zhang W, Zhou HH, Yin JY and Liu ZQ: MicroRNA-138 acts
as a tumor suppressor in non small cell lung cancer via targeting
YAP1. Oncotarget. 7:40038–40046. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma F, Zhang M, Gong W, Weng M and Quan Z:
MiR-138 suppresses cell proliferation by targeting Bag-1 in
gallbladder carcinoma. PLoS One. 10:e01264992015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang B, Mu W, Wang J, Lu J, Jiang S, Li
L, Xu H and Tian H: MicroRNA-138 functions as a tumor suppressor in
osteosarcoma by targeting differentiated embryonic chondrocyte gene
2. J Exp Clin Cancer Res. 35:692016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu Y, Pan ZG, Shu L and Li QJ:
Podocalyxin-like, targeted by miR-138, promotes colorectal cancer
cell proliferation, migration, invasion and EMT. Eur Rev Med
Pharmacol Sci. 22:8664–8674. 2018.PubMed/NCBI
|
|
11
|
Nama S, Muhuri M, Di Pascale F, Quah S,
Aswad L, Fullwood M and Sampath P: MicroRNA-138 is a prognostic
biomarker for triple-negative breast cancer and promotes
tumorigenesis via TUSC2 repression. Sci Rep. 9:127182019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stojcheva N, Schechtmann G, Sass S, Roth
P, Florea AM, Stefanski A, Stühler K, Wolter M, Müller NS, Theis
FJ, et al: MicroRNA-138 promotes acquired alkylator resistance in
glioblastoma by targeting the Bcl-2-interacting mediator BIM.
Oncotarget. 7:12937–12950. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sakamoto KM and Frank DA: CREB in the
pathophysiology of cancer: Implications for targeting transcription
factors for cancer therapy. Clin Cancer Res. 15:2583–2587. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang JQ, Yao QH, Kuang YQ, Ma Y, Yang LB,
Huang HD, Cheng JM, Yang T, Liu EY, Liang L, et al: Prognostic
value of coexistence of abnormal expression of micro-RNA-200b and
cyclic adenosine monophosphate-responsive element-binding protein 1
in human astrocytoma. Hum Pathol. 45:2154–2161. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu L, Guo X, Zhang P, Qi R, Li Z and Zhang
S: Cyclic adenosine monophosphate-responsive element-binding
protein activation predicts an unfavorable prognosis in patients
with hepatocellular carcinoma. Onco Targets Ther. 7:873–879.
2014.PubMed/NCBI
|
|
16
|
Seo HS, Liu DD, Bekele BN, Kim MK, Pisters
K, Lippman SM, Wistuba II and Koo JS: Cyclic AMP response
element-binding protein overexpression: A feature associated with
negative prognosis in never smokers with non-small cell lung
cancer. Cancer Res. 68:6065–6073. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rodon L, Gonzàlez-Juncà A, Inda Mdel M,
Sala-Hojman A, Martínez-Sáez E and Seoane J: Active CREB1 promotes
a malignant TGFβ2 autocrine loop in glioblastoma. Cancer Discov.
4:1230–1241. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Q, Zhang L, Cui Y, Zhang C, Chen H,
Gu J, Qian J and Luo C: Increased RLIP76 expression in IDH1
wildtype glioblastoma multiforme is associated with worse
prognosis. Oncol Rep. 43:188–200. 2020.PubMed/NCBI
|
|
19
|
Qiu S, Huang D, Yin D, Li F, Li X, Kung HF
and Peng Y: Suppression of tumorigenicity by microRNA-138 through
inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma
multiforme. Biochim Biophys Acta. 1832:1697–1707. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Qian J, Wang J, Luo C, Chen J, Hu
G and Lu Y: Knockdown of RLIP76 expression by RNA interference
inhibits invasion, induces cell cycle arrest, and increases
chemosensitivity to the anticancer drug temozolomide in glioma
cells. J Neurooncol. 112:73–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Huang JW, Li M, Cavenee WK,
Mitchell PS, Zhou X, Tewari M, Furnari FB and Taniguchi T:
MicroRNA-138 modulates DNA damage response by repressing histone
H2AX expression. Mol Cancer Res. 9:1100–1111. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Syed SN and Brune B: MicroRNAs as emerging
regulators of signaling in the tumor microenvironment. Cancers
(Basel). 12:9112020. View Article : Google Scholar
|
|
24
|
SiamiGorji S, Jorjani I, Tahamtan A and
Moradi A: Effects of microRNAs polymorphism in cancer progression.
Med J Islam Repub Iran. 34:32020.PubMed/NCBI
|
|
25
|
Sandiford OA, Moore CA, Du J, Boulad M,
Gergues M, Eltouky H and Rameshwar P: Human aging and cancer: Role
of miRNA in tumor microenvironment. Adv Exp Med Biol. 1056:137–152.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Y, Liu X, Cheng L, Li L, Wei Z, Wang
Z, Han G, Wan X, Wang Z, Zhang J and Chen C: Tumor suppressor
microRNA-138 suppresses low-grade glioma development and metastasis
via regulating IGF2BP2. Onco Targets Ther. 13:2247–2260. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chan XH, Nama S, Gopal F, Rizk P, Ramasamy
S, Sundaram G, Ow GS, Ivshina AV, Tanavde V, Haybaeck J, et al:
Targeting glioma stem cells by functional inhibition of a
prosurvival oncomiR-138 in malignant gliomas. Cell Rep. 2:591–602.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alcantara Llaguno SR, Xie X and Parada LF:
Cell of origin and cancer stem cells in tumor suppressor mouse
models of glioblastoma. Cold Spring Harb Symp Quant Biol. 81:31–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aldaz B, Sagardoy A, Nogueira L, Guruceaga
E, Grande L, Huse JT, Aznar MA, Díez-Valle R, Tejada-Solís S,
Alonso MM, et al: Involvement of miRNAs in the differentiation of
human glioblastoma multiforme stem-like cells. PLoS One.
8:e770982013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song H, Zhang Y, Liu N, Zhao S, Kong Y and
Yuan L: MiR-92a-3p exerts various effects in glioma and glioma
stem-like cells specifically targeting CDH1/β-catenin and
Notch-1/Akt signaling pathways. Int J Mol Sci. 17:17992016.
View Article : Google Scholar
|
|
31
|
Sha HH, Wang DD, Chen D, Liu SW, Wang Z,
Yan DL, Dong SC and Feng JF: MiR-138: A promising therapeutic
target for cancer. Tumour Biol. 39:10104283176975752017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Huang H, Xiong Y, Wu Z, He Y, Gao X, Zhou
Z and Wang T: MIR-138-5P inhibits the progression of prostate
cancer by targeting FOXC1. Mol Genet Genomic Med. 8:e11932020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hrdlickova R, Nehyba J, Bargmann W and
Bose HR Jr: Multiple tumor suppressor microRNAs regulate telomerase
and TCF7, an important transcriptional regulator of the Wnt
pathway. PLoS One. 9:e869902014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zheng KB, Xie J, Li YT, Yuan Y, Wang Y, Li
C and Shi YF: Knockdown of CERB expression inhibits proliferation
and migration of glioma cells line U251. Bratisl Lek Listy.
120:309–315. 2019.PubMed/NCBI
|
|
35
|
Robison NJ and Kieran MW: Identification
of novel biologic targets in the treatment of newly diagnosed
diffuse intrinsic pontine glioma. Am Soc Clin Oncol Educ Book.
2012:625–628. 2012. View Article : Google Scholar
|
|
36
|
Di Pascale F, Nama S, Muhuri M, Quah S,
Ismail HM, Chan XH, Sundaram GM, Ramalingam R, Burke B and Sampath
P: C/EBPβ mediates RNA polymerase III-driven transcription of
oncomiR-138 in malignant gliomas. Nucleic Acids Res. 46:336–349.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vollmann-Zwerenz A, Leidgens V, Feliciello
G, Klein CA and Hau P: Tumor cell invasion in glioblastoma. Int J
Mol Sci. 21:19322020. View Article : Google Scholar
|
|
38
|
Ferrer VP, Moura Neto V and Mentlein R:
Glioma infiltration and extracellular matrix: Key players and
modulators. Glia. 66:1542–1565. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhou W, Yu X, Sun S, Zhang X, Yang W,
Zhang J, Zhang X and Jiang Z: Increased expression of MMP-2 and
MMP-9 indicates poor prognosis in glioma recurrence. Biomed
Pharmacother. 118:1093692019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kast RE and Halatsch ME: Matrix
metalloproteinase-2 and −9 in glioblastoma: A trio of old
drugs-captopril, disulfiram and nelfinavir-are inhibitors with
potential as adjunctive treatments in glioblastoma. Arch Med Res.
43:243–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chintala SK, Tonn JC and Rao JS: Matrix
metalloproteinases and their biological function in human gliomas.
Int J Dev Neurosci. 17:495–502. 1999. View Article : Google Scholar : PubMed/NCBI
|
